Toripalimab
Medication / From Wikipedia, the free encyclopedia
Toripalimab, sold under the brand name Loqtorzi, is a monoclonal antibody used for the treatment of melanoma and nasopharyngeal carcinoma.[1][3] Toripalimab is a recombinant humanized programmed cell death protein 1 (PD-1) monoclonal antibody that acts as a checkpoint inhibitor.[4]
Quick Facts Monoclonal antibody, Type ...
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized |
Target | PD-1 |
Clinical data | |
Trade names | Loqtorzi |
Other names | Toripalimab-tpzi |
License data |
|
Drug class | Antineoplastic |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6548H10104N1728O2054S44 |
Molar mass | 147309.54 g·mol−1 |
Close
In 2018, toripalimab was approved in China for the treatment of unresectable or metastatic melanoma that has failed previous systemic therapy.[4] In October 2023, the US Food and Drug Administration (FDA) approved toripalimab for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma when used with cisplatin and gemcitabine.[3][5]